Agilent Technologies, Inc. (A) - Stock Analysis

Last updated: Sep 12, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Agilent reported fiscal Q3 revenue growth of 8.1% and EPS of $1.62 versus $1.48 consensus, then raised its annual profit outlook. Shares gained 13.6% through August 27 and remain near the August 21 high of $159.

Loading chart data...

Idea window: 8/27/2026 – 9/3/2026Sector: Healthcare

AI Analyst Overview

Last Price
$146.80
Market Cap
$41.46B
1D Return
-0.09%
YTD Return
+8.53%

Loading chart data...

Valuation Metrics

P/E
28.8
P/B
5.6
P/S
5.6
EV/EBITDA
23.1
Div Yield
0.69%

Fundamental Analysis

7.0

Key Financial Insights: • Strong Margins • Rising Leverage • Healthy Liquidity Strong profitability and liquidity support the outlook, but rising leverage, intangible-heavy equity, and premium valuation warrant caution.

Profitable
Overvalued

Price Behavior

5.0

Key Price Behavior Insights: • Lower highs • Support holding • Elevated volatility Support Level: $143–$145 Resistance Level: $150–$154 Over the last month, A remains range-bound and volatile, with support at $143–$145 holding but a break above $154 needed to reverse the lower-high trend.

Support
Volatility

Sentiment & News

8.0

Key News Insights: • Revenue beat • Margin expansion • Bullish outlook Agilent's strong Q3 beat, broad-based growth and raised-confidence outlook support a positive near-term investment case.

Agilent
EarningsBeat
AI

AI Summary

6.0
Neutral

Agilent's broad recovery and margin leverage support a shift toward a higher-quality compounder, but at ~29x earnings investors should wait for sustained mid-single-digit organic growth—especially in China and instruments—rather than assume Q3 strength is a durable baseline.

MarginExpansion
ValuationRisk
DiagnosticsGrowth
AI summary updated 2 days ago

Description

Agilent Technologies supplies instruments, consumables and software for life sciences, diagnostics and applied chemical laboratories worldwide. Its offerings span analytical instrumentation (chromatography, mass spectrometry, spectroscopy), cell and molecular biology platforms, genomic assays and laboratory automation, while a dedicated services unit provides columns, consumables, software and operational support. The company sells through direct and indirect channels and is headquartered in Santa Clara, California, incorporated in 1999.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Aug 27Sep 3AAgilent Technologies, Inc.
Agilent reported fiscal Q3 revenue growth of 8.1% and EPS of $1.62 versus $1.48 consensus, then raised its annual profit outlook. Shares gained 13.6% through August 27 and remain near the August 21 high of $159.
Closed-4.9%
Aug 19Aug 26AAgilent Technologies, Inc.
Agilent reported 6.3% organic growth, results above guidance, margin expansion, and higher fiscal 2026 growth and EPS guidance. Shares gained 14.6% through August 19, with fiscal Q3 earnings due August 26.
Closed-0.2%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.